Compare ACHR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHR | GRFS |
|---|---|---|
| Founded | 2018 | 1940 |
| Country | United States | Spain |
| Employees | 1148 | 25247 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.8B |
| IPO Year | N/A | N/A |
| Metric | ACHR | GRFS |
|---|---|---|
| Price | $6.34 | $8.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $12.00 | $10.15 |
| AVG Volume (30 Days) | ★ 26.6M | 646.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.74% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12,475.67 | $5.33 |
| Revenue Next Year | $900.00 | $6.50 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.48 | $6.19 |
| 52 Week High | $14.62 | $11.14 |
| Indicator | ACHR | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 30.52 |
| Support Level | N/A | $7.64 |
| Resistance Level | $7.55 | $9.11 |
| Average True Range (ATR) | 0.41 | 0.30 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 14.13 | 5.19 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.